Evaluating placebo responses to intranasal oxytocin in autism: findings from the placebo lead‐in phase of a randomised controlled trial
This study provides important information about placebo effects and placebo lead-in designs for clinical trials in the autism field. We show widespread clinically significant improvement during placebo lead-in, utility of identifying placebo responders for informing clinical trial analyses, similarities in symptom measure effect sizes for placebo effects, and a lack of influence of caregiver beliefs on placebo responses.
Authors
- Joanna Granich
- Andrew Whitehouse (ORCID: https://orcid.org/0000-0001-8722-1575)
- Adam J. Guastella (ORCID: https://orcid.org/0000-0001-8178-4625)
- Yun Ju Christine Song (ORCID: https://orcid.org/0000-0001-8776-6305)
- Marilena M. DeMayo (ORCID: https://orcid.org/0000-0002-9722-6027)
- Kelsie Boulton (ORCID: https://orcid.org/0000-0002-9408-7367)
- Izabella Pokorski (ORCID: https://orcid.org/0000-0002-1626-9675)
- Zahava Ambarchi
- Emma E. Thomas (ORCID: https://orcid.org/0000-0002-0407-4686)
- Rinku Thapa
- John Wray
- Simon G. Gregory
Institutions
- Duke University (US)
- The Kids Research Institute Australia (AU)
- Children's Hospital at Westmead (AU)
- Sydney Children's Hospital (AU)
- Child, Adolescent and Family Mental Health (CA)
- Ear Science Institute Australia (AU)
Publication Details
- Journal
- Journal of Child Psychology and Psychiatry
- Published
- 2026-01-19
- DOI
- https://doi.org/10.1111/jcpp.70116
- Primary Topic
- Neuroendocrine regulation and behavior
- Type
- article
- Field-Weighted Citation Impact
- 0.00